Safety and efficacy of first-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in newly diagnosed multiple myeloma patients of all ages. IMW 2015, PO-112

Kristian Thidemann Andersen, Maja Hinge, Erik Kay Segel, Tina Ormstrup, Paw Holdgaard, Henrik Boel-Jørgensen, Niels Pallisgaard, Gitte Birk Kerndrup, Torben Plesner

Publikation: Konferencebidrag uden forlag/tidsskriftPosterForskningpeer review

OriginalsprogEngelsk
Publikationsdatosep. 2015
StatusUdgivet - sep. 2015
Begivenhed15th International Myeloma Workshop (IMW) - Rome, Italien
Varighed: 23. sep. 201526. sep. 2015

Konference

Konference15th International Myeloma Workshop (IMW)
LandItalien
ByRome
Periode23/09/201526/09/2015

Citer dette

Andersen, K. T., Hinge, M., Segel, E. K., Ormstrup, T., Holdgaard, P., Boel-Jørgensen, H., ... Plesner, T. (2015). Safety and efficacy of first-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in newly diagnosed multiple myeloma patients of all ages. IMW 2015, PO-112. Poster session præsenteret på 15th International Myeloma Workshop (IMW), Rome, Italien.
Andersen, Kristian Thidemann ; Hinge, Maja ; Segel, Erik Kay ; Ormstrup, Tina ; Holdgaard, Paw ; Boel-Jørgensen, Henrik ; Pallisgaard, Niels ; Kerndrup, Gitte Birk ; Plesner, Torben. / Safety and efficacy of first-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in newly diagnosed multiple myeloma patients of all ages. IMW 2015, PO-112. Poster session præsenteret på 15th International Myeloma Workshop (IMW), Rome, Italien.
@conference{b9c9fc5a83df46a38a8ac529fa19cda5,
title = "Safety and efficacy of first-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in newly diagnosed multiple myeloma patients of all ages. IMW 2015, PO-112",
author = "Andersen, {Kristian Thidemann} and Maja Hinge and Segel, {Erik Kay} and Tina Ormstrup and Paw Holdgaard and Henrik Boel-J{\o}rgensen and Niels Pallisgaard and Kerndrup, {Gitte Birk} and Torben Plesner",
year = "2015",
month = "9",
language = "English",
note = "15th International Myeloma Workshop (IMW) ; Conference date: 23-09-2015 Through 26-09-2015",

}

Andersen, KT, Hinge, M, Segel, EK, Ormstrup, T, Holdgaard, P, Boel-Jørgensen, H, Pallisgaard, N, Kerndrup, GB & Plesner, T 2015, 'Safety and efficacy of first-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in newly diagnosed multiple myeloma patients of all ages. IMW 2015, PO-112', 15th International Myeloma Workshop (IMW), Rome, Italien, 23/09/2015 - 26/09/2015.

Safety and efficacy of first-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in newly diagnosed multiple myeloma patients of all ages. IMW 2015, PO-112. / Andersen, Kristian Thidemann; Hinge, Maja; Segel, Erik Kay; Ormstrup, Tina; Holdgaard, Paw; Boel-Jørgensen, Henrik; Pallisgaard, Niels; Kerndrup, Gitte Birk; Plesner, Torben.

2015. Poster session præsenteret på 15th International Myeloma Workshop (IMW), Rome, Italien.

Publikation: Konferencebidrag uden forlag/tidsskriftPosterForskningpeer review

TY - CONF

T1 - Safety and efficacy of first-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in newly diagnosed multiple myeloma patients of all ages. IMW 2015, PO-112

AU - Andersen, Kristian Thidemann

AU - Hinge, Maja

AU - Segel, Erik Kay

AU - Ormstrup, Tina

AU - Holdgaard, Paw

AU - Boel-Jørgensen, Henrik

AU - Pallisgaard, Niels

AU - Kerndrup, Gitte Birk

AU - Plesner, Torben

PY - 2015/9

Y1 - 2015/9

M3 - Poster

ER -

Andersen KT, Hinge M, Segel EK, Ormstrup T, Holdgaard P, Boel-Jørgensen H et al. Safety and efficacy of first-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in newly diagnosed multiple myeloma patients of all ages. IMW 2015, PO-112. 2015. Poster session præsenteret på 15th International Myeloma Workshop (IMW), Rome, Italien.